Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: Present and future implications

Biochemical Pharmacology

Volumn 55, Issue 11, 1998, Pages 1741-1746

  Taglialatela, Maurizio ^a   Castaldo, Pasqualina ^a   Pannaccione, Anna ^a   Giorgio, Giovanna ^a   Annunziato, Lucio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antiarrhythmics; Human arrhythmias; Humans ether a gogo related gene (HERG) K+ channels; Long QT syndrome; Oxygen free radicals; Second generation antihistamines

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; DOFETILIDE; EBASTINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; IBUTILIDE FUMARATE; LORATADINE; POTASSIUM CHANNEL; POTASSIUM ION; PSYCHOTROPIC AGENT; TERFENADINE; TERIKALANT; THIORIDAZINE;

BINDING AFFINITY; CARDIOTOXICITY; DRUG BINDING SITE; DRUG MECHANISM; HEART ARRHYTHMIA; HEART MUSCLE REPERFUSION; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; OXIDATIVE STRESS; PHARMACOLOGICAL STIMULATION; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN STRUCTURE; QT INTERVAL; REVIEW; SEX DIFFERENCE; TORSADE DES POINTES;

EID: 0032101646     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00002-1     Document Type: Article

References (67)

1. Carmeliet E. Mechanisms and control of repolarization. Eur Heart J. 14:1993;3-13.
2. + current Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 96:1990;195-215.
3. Schwartz P.J., Locati E.H., Napolitano C., Priori S.G. The long QT syndrome. Zipes D.P., Jalife J. Cardiac Electrophysiology. From Cell to Bedside. 2nd Edn :1995;788-811 W. B. Saunders, Philadelphia.
4. VLQT1 mutations cause cardiac arrhythmias. Nature Genet. 12:1996;17-23.
5. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia HERG mutations cause long QT syndrome . Cell. 80:1995;795-803.
6. Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J.L., Moss A.J., Towbin J.A., Keating M.T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 80:1995;805-811.
7. Keating M.T. Genetic approaches to cardiovascular diseases. Circulation. 92:1995;142-147.
8. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J and Vincent GM, for the SADS Foundation Task Force on LQTS, Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps and future directions. Circulation 94: 1996-2012, 1996.
9. Warmke J.W., Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA. 91:1994;3438-3442.
10. + channel function. Kidney Int. 48:1995;918-922.
11. Li X., Xu J., Li M. The human Δ1261 mutation of the HERG potassium channel results in a truncated protein that contains a subunit interaction domain and decreases the channel expression. J Biol Chem. 272:1997;705-708.
12. +-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA. 93:1996;2208-2212.
13. Tanaka T., Nagai R., Tomoike H., Takata S., Yano K., Yabuta K., Haneda N., Nakano O., Shibata A., Sawayama T., Kasai H., Yazaki Y., Nakamura Y. Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome. Circulation. 95:1997;565-567.
14. Dausse E., Berthet M., Denjoy I., André-Fouet X., Cruaud C., Bennaceur M., Fauré S., Coumel P., Schwartz K., Guicheney P. A mutation in HERG associated with notched T waves in long QT syndrome. J Mol Cell Cardiol. 28:1996;1609-1615.
15. Benson D.W., MacRae C.A., Vesely M.R., Walsh E.P., Seidman J.G., Seidman C.E., Satler C.A. Missense mutation in the pore region of HERG causes familial long QT syndrome. Circulation. 93:1996;1791-1795.
16. Satler C.A., Walsh E.P., Vesely M.R., Plummer M.H., Ginsburg G.S., Jacob H.J. Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome. Am J Med Genet. 65:1996;27-35.
17. Kr potassium channel . Cell. 81:1995;299-307.
18. Smith P.L., Baukrowitz T., Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature. 379:1996;833-836.
19. Schönherr R., Heinemann S.H. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J Physiol (Lond). 493:1996;635-642.
20. + channel, erg. Circ Res. 80:1997;261-268.
21. + current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. J Physiol (Lond). 489:1995;455-471.
22. + channel in rat F-11 DRG cell line Pharmacological identification and biophysical characterization . J Physiol (Lond). 496:1996;13-23.
23. + channels Spike-frequency adaptation . J Physiol (Lond). 501:1997;313-318.
24. + channel polypeptide is encoded by the seizure locus. J Neurosci. 17:1997;875-881.
25. Wang X., Reynolds E.R., Déak P., Hall L.M. The seizure locus encodes the Drosophila homolog of the HERG potassium channel. J Neurosci. 17:1997;882-890.
26. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 321:1989;406-410.
27. Yusuf S., Teo K.K. Approaches to prevention of sudden death Need for fundamental re-evaluation . J Cardiovasc Electrophysiol. 2:1991;S233-S239.
28. Singh B.N. Arrhythmia control by prolonging repolarization The concept and its potential therapeutic impact . Eur Heart J. 14:1993;14-23.
29. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ and Veltri EP, for the SWORD investigators, Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348: 7-12, 1996.
30. Kaumann A.J., Olson C.B. Temporal relation between long-lasting aftercontractions and action potentials in cat papillary muscles. Science. 163:1968;293-295.
31. Ks cardiac potassium current. Nature. 384:1996;78-80.
32. Ks potassium channels. Nature. 384:1996;80-83.
33. Kiehn J., Lacerda A.E., Wible B., Brown A.M. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation. 94:1996;2575-2579.
34. Snyders D.J., Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol. 49:1996;949-955.
35. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 269:1995;92-95.
36. Kr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation. 91:1995;1799-1806.
37. Kr. Circulation. 94:1996;2938-2946.
38. Kiehn J., Wible B., Ficker E., Taglialatela M., Brown A.M. Cloned human inward rectifier potassium channel as a target for class III cardiac methanesulfonanilides. Circ Res. 77:1995;1151-1155.
39. Rees S.A., Curtis M.J. Specific IK1 blockade A new antiarrhythmic mechanism? Effect of RP 58866 on ventricular arrhythmias in rat, rabbit, and primate . Circulation. 87:1993;1979-1989.
40. minK channel complex. Trends Pharmacol Sci. 18:1997;26-29.
41. + channels expressed in Xenopus oocytes. Am J Physiol. 272:1997;H1309-H1314.
42. Babe K.S. Jr, Serafin W.E. Histamine, bradykinin and their antagonists. Hardman J.G., Limbird L.E. Goodman and Gilman's The Pharmacological Basis of Therapeutics. IX Edn :1996;581-600 McGraw-Hill, New York.
43. Sorkin E.M., Heel R.C. Terfenadine A review of its pharmacodynamic properties and therapeutic efficacy . Drugs. 29:1985;34-56.
44. Woosley R.L. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 36:1996;233-252.
45. Jackman W.M., Friday K.J., Anderson J.L., Aliot E.M., Clark M., Lazzara R. The long QT syndrome A critical review, new clinical observations and a unifying hypothesis . Prog Cardiovasc Dis. 31:1988;115-172.
46. Davies A.J., Harinda V., McHewan A., Ghose R.R. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J. 298:1989;325.
47. Craft T.M. Torsade de pointes after astemizole overdose. Br Med J. 292:1986;660.
48. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., Cantilena L.R. Torsade de pointes occurring in association with terfenadine use. JAMA. 264:1990;2788-2790.
49. Berul C.I., Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation. 91:1995;2220-2225.
50. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 76:1995;110-119.
51. Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic action of terfenadine. JAMA. 269:1993;1532-1536.
52. Roy M-L, Dumaine R., Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 94:1996;817-823.
53. Suessbrich H., Waldegger S., Lang F., Busch A.E. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385:1996;77-80.
54. + channel family by ebastine. J Pharmacol Exp Ther. 281:1997;233-244.
55. Haria M., Fitton A., Peters D.H. Loratadine. A reappraisal of its pharmacodynamic properties and therapeutic use in allergic disorders. Drugs. 48:1994;617-638.
56. Suessbrich H., Schönher R., Heinemann S.H., Attali B., Lang F., Busch A.E. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 120:1997;968-974.
57. Kaneko M., Matsumoto Y., Hayashi H., Kobayashi A., Yamazaki N. Oxygen free radicals and calcium homeostasis in the heart. Mol Cell Biochem. 139:1994;91-100.
58. + channels by reactive oxygen species. Proc Natl Acad Sci USA. 94:1997;11698-11703.
59. Becker L.C., Ambrosio G. Myocardial consequences of reperfusion. Prog Cardiovasc Dis. 30:1987;23-44.
60. Coyle J.T., Puttfarcker P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
61. Monyer H., Hartley D.M., Choi D.W. 21-Aminosteroids attenuate excitotoxic neuronal injury in cortical cell cultures. Neuron. 5:1990;121-126.
62. Chan P.H., Kinouchi H., Epstein C.J., Carlson E., Chen S.F., Imaizumi S., Yang G.Y. Role of superoxide dismutase in ischemic brain injury Reduction of edema and infarction in transgenic mice following focal cerebral ischemia . Prog Brain Res. 96:1993;97-104.
63. Martin R.L., Lloyd H.G.E., Cowan A.I. The early events of oxygen and glucose deprivation Setting the scene for neuronal death? Trends Neurosci. 17:1994;251-257.
64. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., Lehmann M.H. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA. 270:1993;2590-2597.
65. Behl C., Widmann M., Trapp T., Holsboer F. 17-β Estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 216:1995;473-482.
66. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 92:1995;3381-3386.
67. 2+ and modulated by cAMP. Nature. 365:1993;445-448.